We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$272M
AUM Growth
-$70.2M
Cap. Flow
-$30.4M
Cap. Flow %
-11.2%
Top 10 Hldgs %
40.84%
Holding
92
New
12
Increased
37
Reduced
27
Closed
16

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$8.78M
2
WAT icon
Waters Corp
WAT
+$8.33M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$6.57M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.23M
5
UTHR icon
United Therapeutics
UTHR
+$3.6M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.76M
2
ABBV icon
AbbVie
ABBV
+$7.41M
3
IDXX icon
Idexx Laboratories
IDXX
+$5.14M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.09M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 96.48%
2 Industrials 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$23.1B
$21.6M 7.97%
91,806
+17,699
+24% +$3.6M
UNH icon
2
UnitedHealth
UNH
$370B
$14.8M 5.45%
28,811
+3,484
+14% +$1.75M
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
$13.6M 4.99%
76,626
-9,470
-11% -$1.36M
DHR icon
4
Danaher
DHR
$144B
$9.75M 3.59%
43,390
+1,686
+4% +$388K
XENE icon
5
Xenon Pharmaceuticals
XENE
$6.12B
$8.96M 3.3%
294,559
-9,627
-3% -$291K
WAT icon
6
Waters Corp
WAT
$39.9B
$8.69M 3.2%
+26,250
New +$8.33M
IQV icon
7
IQVIA
IQV
$39.3B
$8.62M 3.17%
39,701
-10,389
-21% -$2.26M
ELV icon
8
Elevance Health
ELV
$85.5B
$8.57M 3.15%
+17,750
New +$8.78M
NBIX icon
9
Neurocrine Biosciences
NBIX
$16.6B
$8.34M 3.07%
85,589
+22,355
+35% +$2.06M
IRTC icon
10
iRhythm Holdings
IRTC
$4.2B
$7.99M 2.94%
74,001
-29,980
-29% -$3.97M
CTLT
11
DELISTED
CATALENT, INC.
CTLT
$7.25M 2.67%
67,618
-11,431
-14% -$1.16M
CDMO
12
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$7.04M 2.59%
461,226
+53,768
+13% +$795K
ALT icon
13
Altimmune
ALT
$599M
$6.55M 2.41%
559,755
+250,169
+81% +$1.54M
LEGN icon
14
Legend Biotech
LEGN
$4.01B
$6.48M 2.39%
117,807
-2,666
-2% -$113K
IONS icon
15
Ionis Pharmaceuticals
IONS
$9.4B
$6.45M 2.38%
+174,300
New +$6.57M
CTIC
16
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$6.28M 2.31%
1,051,047
+826,047
+367% +$4.23M
AVTR icon
17
Avantor
AVTR
$9.19B
$5.36M 1.97%
172,269
+13,904
+9% +$434K
CVS icon
18
CVS Health
CVS
$122B
$4.96M 1.83%
53,547
-32,071
-37% -$3.13M
THC icon
19
Tenet Healthcare
THC
$21.1B
$4.85M 1.78%
92,190
-46,995
-34% -$3.27M
RCM
20
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.83M 1.78%
230,413
-112,510
-33% -$2.55M
CNCE
21
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$4.73M 1.74%
1,124,072
+746,673
+198% +$2.95M
RCUS icon
22
Arcus Biosciences
RCUS
$3.64B
$4.34M 1.6%
171,214
+3,893
+2% +$95.3K
ACRS icon
23
Aclaris Therapeutics
ACRS
$869M
$4.26M 1.57%
304,843
-363,255
-54% -$5.09M
ATEC icon
24
Alphatec Holdings
ATEC
$1.44B
$3.42M 1.26%
523,735
+71,941
+16% +$663K
COO icon
25
Cooper Companies
COO
$14.5B
$3.29M 1.21%
42,000
-36,340
-46% -$3.22M
1
2 3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Parkman Healthcare Partners held 92 positions worth $272M, down 21% from $342M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Parkman Healthcare Partners withdrew a net $30.4M in Q2 2022, closing 16 positions and reducing 27 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $7.76M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Elevance Health worth $8.57M.

  • Parkman Healthcare Partners's largest Q2 2022 buy was Elevance Health: 17,750 shares worth $8.57M.
  • Parkman Healthcare Partners added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2022, an estimated $4.23M increase.
  • Parkman Healthcare Partners's biggest Q2 2022 reduction was Aclaris Therapeutics, cutting an estimated $5.09M.
  • Parkman Healthcare Partners fully exited BioCryst Pharmaceuticals in Q2 2022, selling an estimated $7.76M.
  • Parkman Healthcare Partners's ten largest holdings make up 41% of its $272M portfolio in Q2 2022.
  • Parkman Healthcare Partners opened 12 new positions and closed 16 in Q2 2022.
  • Parkman Healthcare Partners's portfolio value fell 21% quarter-over-quarter to $272M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2022, filed 12 Aug 2022.